Schutten JC, Joris PJ, Minović I, et al. - Researchers conducted a post‐hoc analysis of a previously performed double‐blind placebo‐controlled intervention trial to examine the effect of long‐term oral magnesium supplementation (350 mg/day) on glucocorticoid metabolism, specifically on the excretion of urinary cortisol, cortisone and their metabolites, as well as on the ratios reflecting enzymatic activity of 11β‐hydroxysteroid dehydrogenases (11β‐HSDs) and A‐ring reductases. Participants in the study were 49 overweight men and women, aged between 45 and 70 years. The beneficial effect of magnesium supplementation on lower 24-h urinary cortisol excretion was observed along with an increased 11β-HSD type 2 activity. The findings may provide another potential mechanism by which increased intake of magnesium reduces the risk of CVD.